APA (7th ed.) Citation

J, G., J, C., E, S., A, F., S, C., I, M., . . . D, H. (2023). Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta neuropathologica, 145(5), 651. https://doi.org/10.1007/s00401-023-02566-0

Chicago Style (17th ed.) Citation

J, Goddard, et al. "Molecular Characterisation Defines Clinically-actionable Heterogeneity Within Group 4 Medulloblastoma and Improves Disease Risk-stratification." Acta Neuropathologica 145, no. 5 (2023): 651. https://doi.org/10.1007/s00401-023-02566-0.

MLA (9th ed.) Citation

J, Goddard, et al. "Molecular Characterisation Defines Clinically-actionable Heterogeneity Within Group 4 Medulloblastoma and Improves Disease Risk-stratification." Acta Neuropathologica, vol. 145, no. 5, 2023, p. 651, https://doi.org/10.1007/s00401-023-02566-0.